MaxMarioni
Member Since 23 November 2015
Offline
Last Seen: 20 Jan '18

MaxMarioni's Insights

Relating to GSK.L

Hikma pharmaceuticals (HIK:LN) was the best performing stock at the end of last week, experiencing a rise of 4.19% on Friday. This means the stock is now valued at 2,165p. The stock, which debuted on the FTSE 100 only last year, rose on the back of its earnings announcement for the first half of 2016. The healthcare company reported that its revenue rose by 24% to $882 million, or 28% in constant currency terms. (Read more)

0 Comments 0 Likes 0 ScrapbooksRead More >

Shire PLC, the Dublin-based pharmaceutical company at the centre of the controversial merger with Astrazeneca which fell through earlier this year, has announced its 2016 quarterly results which beat analysts' estimates. Pharmaceuticals have grown more and more appealing as prospective equity investments for investors given the growth potential of healthcare products driven by profound global demographic shifts. Sales in the multibillion-dollar global healthcare sector grew by 9.5% in 2015, particularly in emerging markets. (Read more)

0 Comments 0 Likes 0 ScrapbooksRead More >